Skip to main content

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Completed · Phase 2 · NCT04975893

Conditions: Cytomegalovirus Infection

At a glance

Research payments reported, 2025
$281,001
U.S. investigators named
6
Sites paid
6
Planned or actual enrollment
135

About the trial

Sponsor
ModernaTX, Inc.
Tested
mRNA-1647 (biological), mRNA-1647 (other)
Dates
Started 2021-06-18; completion 2026-01-19
Results posted
Not yet

The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202 (NCT04232280). For participants in the optional booster phase (BP), the main purpose is to evaluate the long-term immunogenicity and safety of the mRNA-1647 vaccine in both participants receiving a booster dose (BD) and those not receiving a BD, and to additionally evaluate the reactogenicity in participants receiving a BD.

From ClinicalTrials.gov, last updated 2026-02-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

ModernaTX, Inc. reported $281,001 in research payments for this study in 2025 (80 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • J Lewis Research Inc $123,980
  • Alliance for Multispecialty Research LLC $86,284
  • Tekton Research LLC $29,966
  • Johnson County Clin-Trials $24,667
  • Crossroads Clinical Research $10,370
  • Alliance for Multispecialty $5,734

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.